Literature DB >> 26131881

Evaluation of the therapeutic results of actinic keratosis treated with topical 5% fluorouracil by reflectance confocal laser microscopy: preliminary study.

Priscila Ishioka1, Marcus Maia2, Sarita Bartholomei Rodrigues2, Alessandra Cristina Marta2, Sérgio Henrique Hirata1.   

Abstract

Topical treatment for actinic keratosis with 5% fluorouracil has a recurrence rate of 54% in 12 months of follow-up. This study analyzed thirteen actinic keratoses on the upper limbs through confocal microscopy, at the time of clinical diagnosis and after 4 weeks of treatment with fluorouracil. After the treatment was established and evidence of clinical cure was achieved, in two of the nine actinic keratoses, confocal microscopy enabled visualization of focal areas of atypical honeycomb pattern in the epidermis indicating therapeutic failure. Preliminary data suggest the use of confocal microscopy as a tool for diagnosis and therapeutic control of actinic keratosis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26131881      PMCID: PMC4516112          DOI: 10.1590/abd1806-4841.20153437

Source DB:  PubMed          Journal:  An Bras Dermatol        ISSN: 0365-0596            Impact factor:   1.896


Actinic keratosis (AK) is a pre-neoplastic lesion with a transformation degree into squamous cell carcinoma of 0.1 to 20%. [1],[2] Fluorouracil (FU), one of the therapeutic alternatives for AK, presented a recurrence frequency of 54% in 12 months of follow-up. [3] Topical use of 5-FU for 2 to 4 weeks has a recommendation degree II and a category B level of evidence with 96% clinical rate and 67% histological rate of cure. [4],[5] With the goal of increasing diagnostic accuracy and therapeutic control of AK, non-invasive methods were described such as the use of dermoscopy and recently reflectance confocal laser microscopy (RCLM). RCLM is a non-invasive examination, which allows the visualization in vivo of structures and cells with similar resolution to histology. [6] RCLM has a sensitivity of 80% and specificity of 98.6% for the diagnosis of AK. [7] RCLM of AK is characterized by the finding of small ruptures in the corneal layer and the presence of isolated keratinocytes, which are visualized as polygonal and hyper refractory. Parakeratosis is represented by the presence of nucleated cells with dark center and marked peripheral halo. In the granular and spinous layer an architectural disarray is observed (atypical honeycomb) with nucleated round cells of varied sizes, which histologically represent the dysplasia of keratinocytes. In the upper dermis, round dilated vessels and moderately refractory linear structures are observed, which correspond to solar elastosis. [8],[9] Ulrich et al in 2010 described the applicability of RCLM in the therapeutic follow-up of AK with imiquimod and emphasized the importance of the method in the recognition of subclinical actinic lesions. [10] These data stimulated us to develop a similar and unprecedented study, with the objective of analyzing, through RCLM, the response of AK treatment with FU. A preliminary study was conducted at the confocal microscopy outpatient clinic of the dermatology department of the charity hospital Santa Casa de Misericórdia de São Paulo - SP, from January to December of 2013, after approval by the research ethics committee. Thirteen AK on the upper limbs of seven patients, clinically diagnosed, were recorded and analyzed through RCLM, at the time of clinical diagnosis and again after 4 weeks of treatment with 5% FU cream divided into 2 cycles. Each cycle corresponded to 2 weeks of occlusive FU every 12 hours, followed by 2 weeks with almond oil. Post-treatment imagery were obtained from clinically cured AK patients. Capture of clinical digital images were performed with an Iphone 4S® camera. Skin marking of lesions was made with a ballpoint pen and panoramic photograph of the region. For the RCLM examination, a Vivascope 1500® device was used. The detailed description of the technique and device has already been reported in other publications. Transversal 5x5mm images were captured of all epidermal strata (corneal, granular and spinous) and of superficial dermis. Each captured image was analyzed by two dermatologists, simultaneously, experienced in confocal microscopy, before and after introduction of FU, as to the presence of the following characteristics: rupture of corneal layer with nucleated polygonal cells; epidermis (granular and spinous layers) in a honeycomb arrangement (atypical) and round nucleated cells; dilated vessels, round and solar elastosis in dermis. Exclusion criteria: hypertrophic AK and/or with clinical suspicion of malignant transformation. The thirteen AK belonged to patients of Fitz-patrick's phototypes I and II, with mean age of 69.7. RCLM of AK before establishing the treatment, in all patients, revealed granular and spinous layers with n irregular honeycomb and nucleated round cells (Figure 1). A corneal layer with ruptures and presence of polygonal cells was observed, isolated, in 77% of the cases and revealed only 31% of lesions as having solar elastosis and rounded dilated vessels in the dermis. Two patients (four AK) were excluded from the study because they developed contact dermatitis to FU. Post-treatment: RCLM of the nine AK, submitted to treatment and with clinical cure, demonstrate corneal layer without changes, absence of ruptures and/or nucleated polygonal cells. In seven of the nine cases treated, it was visualized regular granular and spinous layers, typical, without rounded cells. In two AK, small isolated areas of atypical honeycomb with rounded cells in the granular and spinous layers (Figure 2) were observed by means of RCLM. The presence of dilated vessels and of elastosis in the dermis was observed in 11% and 22%, respectively.
FIGURE 1

Image of confocal microscopy of actinic keratosis with architectural disarray in the granular and spinous layers (atypical honeycomb) with pleomorphism of keratinocytes

FIGURE 2

Image of confocal microscopy of actinic keratosis treated with topical 5% fluorouracil demonstrating focal area of atypical honeycomb

Image of confocal microscopy of actinic keratosis with architectural disarray in the granular and spinous layers (atypical honeycomb) with pleomorphism of keratinocytes Image of confocal microscopy of actinic keratosis treated with topical 5% fluorouracil demonstrating focal area of atypical honeycomb In this study, the RCLM of AK presented an atypical honeycomb with rounded cells, located in the epidermis in 100% of the cases. This data reaffirms that the presence of architectural disarray and cellular pleomorphism are the best predictors for the diagnosis of AK, also described by Ulrich et al.[7],[9] The finding of solar elastosis and rounded vessels in only 31% of the cases may be due to presence of adherent scales on the surface, which makes the visualization of deeper structures difficult. Ulrich et al in 2008 also observed low concordance among the examiners in the analysis of dermal changes when evaluating 46 AK patients.[7] All treated AK achieved clinical cure, and in two of nine lesions, RCLM allowed the visualization of focal areas of atypical honeycomb, with atypical cells, in the granular and spinous layers, suggesting therapeutic failure. This protocol is a work in progress, however, since the preliminary data suggested the use of RCLM as a tool for diagnosis and therapeutic control of AK, in our judgment this prior notice would be of scientific importance.
  9 in total

1.  In vivo confocal scanning laser microscopy of human skin II: advances in instrumentation and comparison with histology.

Authors:  M Rajadhyaksha; S González; J M Zavislan; R R Anderson; R H Webb
Journal:  J Invest Dermatol       Date:  1999-09       Impact factor: 8.551

2.  Clinical applicability of in vivo reflectance confocal microscopy for the diagnosis of actinic keratoses.

Authors:  Martina Ulrich; Adrienne Maltusch; Francisca Rius-Diaz; Joachim Röwert-Huber; Salvador González; Wolfram Sterry; Eggert Stockfleth; Susanne Astner
Journal:  Dermatol Surg       Date:  2008-02-08       Impact factor: 3.398

Review 3.  Actinic keratoses.

Authors:  J P Callen; D R Bickers; R L Moy
Journal:  J Am Acad Dermatol       Date:  1997-04       Impact factor: 11.527

Review 4.  Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: Critical review and meta-analysis of efficacy studies.

Authors:  Aditya K Gupta; Valerie Davey; Heather Mcphail
Journal:  J Cutan Med Surg       Date:  2005-10       Impact factor: 2.092

5.  The risk of progression to invasive disease.

Authors:  R G Glogau
Journal:  J Am Acad Dermatol       Date:  2000-01       Impact factor: 11.527

6.  Confocal laser microscopic imaging of actinic keratoses in vivo: a preliminary report.

Authors:  D Aghassi; R R Anderson; S González
Journal:  J Am Acad Dermatol       Date:  2000-07       Impact factor: 11.527

7.  Reflectance confocal microscopy for noninvasive monitoring of therapy and detection of subclinical actinic keratoses.

Authors:  M Ulrich; D Krueger-Corcoran; J Roewert-Huber; W Sterry; E Stockfleth; S Astner
Journal:  Dermatology       Date:  2009-11-11       Impact factor: 5.366

8.  Reflectance confocal microscopy criteria for squamous cell carcinomas and actinic keratoses.

Authors:  Ayelet Rishpon; Nancy Kim; Alon Scope; Leeor Porges; Margaret C Oliviero; Ralph P Braun; Ashfaq A Marghoob; Christi Alessi Fox; Harold S Rabinovitz
Journal:  Arch Dermatol       Date:  2009-07

9.  A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up.

Authors:  N Krawtchenko; J Roewert-Huber; M Ulrich; I Mann; W Sterry; E Stockfleth
Journal:  Br J Dermatol       Date:  2007-12       Impact factor: 9.302

  9 in total
  1 in total

Review 1.  Updates on the Management of Non-Melanoma Skin Cancer (NMSC).

Authors:  Artur Fahradyan; Anna C Howell; Erik M Wolfswinkel; Michaela Tsuha; Parthiv Sheth; Alex K Wong
Journal:  Healthcare (Basel)       Date:  2017-11-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.